Development asset linked to Esperion Therapeutics in public FDA and regional records.
pharma · Hypercholesterolemia · Hyperlipidemia · ESPR
Esperion Therapeutics
Esperion Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ann Arbor, US
- Employees
- 5
- Programs
- 15
- Drugs
- 9
- Patents
- 55
Esperion Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Esperion Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bempedoic acid
Cardiovascular system (C10)US regulatory status: approved. Molecular target: ATP-citrate synthase.
- Target
- ATP-citrate synthase
- Mechanism
- ATP-citrate synthase inhibitor
-
US regulatory status: approved.
-
Development asset linked to Esperion Therapeutics in public FDA and regional records.
-
Development asset linked to Esperion Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.
- Target
- NPC1-like intracellular cholesterol transporter 1
- Mechanism
- Niemann-Pick C1-like protein 1 inhibitor
-
Development asset linked to Esperion Therapeutics in public FDA and regional records.
-
Development asset linked to Esperion Therapeutics in public FDA and regional records.